| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | D+ | 38 | Negative earnings, depressed valuation multiples, weak 52-week performance offset by low beta and dividend support | 6–12M |
| SA Quality/Value Composite | D | 32 | EPS: −$20.00 (deep loss); forward P/E: 5.61x (distressed); no profitability flags; revenue declining YoY −16.63% | 1–3M |
| Zacks Earnings Momentum | F | 15 | EPS negative; eps_growth_yoy: null (no forward consensus visible); earnings date not available; turnaround trajectory unclear | 1–3M |
| Institutional & Smart Money Flow | B | 72 | Today's +15.68% intraday surge on moderate volume (avg 3.48M sh/d) suggests institutional accumulation; recovery narrative emerging | 1–3M |
| Growth Sustainability & Moat | D | 28 | Revenue contraction (−16.63% YoY); no earnings; hyper_growth flag: false; chemical sector cyclicality; moat assessment constrained by profitability collapse | 6–12M |
| Valuation & Safety (Pre-Penalty) | B | 68 | Forward P/E 5.61x (deeply discounted); 52-week range $9.95–$42.77 (stock off −76.21%); dividend yield 3.20% (supported); enterprise value $1.31B; low absolute valuation multiple | 6–12M |
| Penalty Overlay (Loss, Turnaround Risk) | F | 10 | Large negative EPS (−$20.00); no profitability; dividend under stress if losses persist; balance sheet transparency constrained; recovery unproven | 1–3M |
| CONFIDENCE SCORE | C | 54 | Earnings data missing; forward guidance absent; profile coverage gaps; price action today is positive signal but fundamentals opaque; beta 0.42 provides stability | 1–3M |
| Volatility & Drawdown Risk | A | 82 | Beta 0.42 (very low systematic risk); 52-week drawdown from $42.77 to $9.95 (−76.21%) is historical; current proximity to 52-week low suggests limited further downside cushion | 1–3M |
| Crowding Risk Flag | C | 56 | Large intraday gain (+15.68%) suggests retail/momentum participation; low avg volume (3.48M) indicates potential for liquidity stress if selling resumes; turnaround plays attract crowded trades | 1–3M |
FMC Corp operates in the Chemicals sector—a capital-intensive, cyclical industry sensitive to agricultural demand, input costs, and macro conditions. At −76% from 52-week highs, FMC is trading at distressed valuations typical of turnaround candidates; a forward P/E of 5.61x reflects deep market skepticism on earnings recovery. Revenue contraction of −16.63% YoY aligns with sector headwinds but raises sustainability concerns. Peers in specialty chemicals (e.g., Scotts Miracle-Gro, CF Industries, Hawkins Inc.) have experienced similar pressures, though recovery timing and magnitude vary widely. FMC's low beta (0.42) suggests defensive characteristics, while the 3.20% dividend yield provides income support—critical for distressed investors. The sharp intraday rally (+15.68%) today may reflect positive catalysts (earnings beat, strategic announcement, or sector rotation), but fundamental opacity limits conviction.
Momentum Risk / Reward: Today's +15.68% move is a tactically positive signal, suggesting institutional interest in a recovery narrative. However, with no visible earnings guidance, forward consensus, or earnings date disclosed, conviction remains low. Crowding risk is elevated: retail/momentum traders may participate in mean-reversion trades, creating whipsaw potential. Watch for next earnings announcement and management commentary on cost structure, market demand stabilization, and dividend sustainability. Technical support near $9.95 (52-week low) offers a downside anchor; resistance around $12–$13 is likely. Tactical posture: cautious accumulation for value players; avoid overweight on momentum alone.
Fundamental Turnaround Dependency: Medium-term thesis hinges entirely on revenue stabilization and a return to profitability. The −16.63% revenue decline must reverse; current losses (EPS −$20.00) cannot persist without jeopardizing the dividend. Chemical sector cyclicals typically recover when macro conditions improve (ag commodity prices, industrial demand). A successful turnaround would justify re-rating from 5.61x forward P/E to 10–15x, implying 75–165% upside from $11.58. However, downside to dividend cut and further multiple compression is material if revenue stalls. Key event risk: Q2/Q3 earnings, capital allocation updates, and industry-wide demand signals. Conviction case: suitable for deep-value, high-risk-tolerance investors; unsuitable for income-focused or risk-averse portfolios.
FMC Analyst Price Target Forecast - ESEN Analytics
FMC analyst price target: $17.0 average (range $13.0-$26.0), based on 31 Wall Street analysts.
Analysis by ESEN Analytics Systems (esenglobalinvest.com), an AI-driven US equity research platform covering 5,000+ US stocks.
FMC Stock Analysis & Forecast
Is FMC a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
FMC Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, FMC shows balanced risk-reward characteristics.
Should You Buy FMC Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in FMC.